Prostate cancer light micrograph v3

New Treatment Possibilities and Superior Outcomes for Patients With Prostate Cancer

City of Hope Trial Evaluates White Button Mushroom Supplement to Reduce PSA Levels

City of Hope, in collaboration with the National Cancer Institute, is conducting a Phase 2 trial to further evaluate the use of a white button mushroom supplement to reduce PSA levels in patients with prostate cancer.

Results from a Phase 1 trial indicated that white button mushroom extract was potentially effective against prostate cancer. About 36% of study participants experienced a decline in PSA levels after three months of supplement consumption, and no dose-limiting toxicities were observed. There were also no negative adverse side effects. 

The objective of the Phase 2 trial is to measure adverse events and assess the relative change in PSA levels at 48 weeks in recurrent prostate cancer patients following local therapy and in therapy-naïve patients with favorable risk prostate cancer who are undergoing active surveillance.

Experimental groups will consume 14 grams of a mushroom powder tablet every four weeks for cycles 1-3 then every 12 weeks for cycles 4-6 in the absence of disease progression or unacceptable toxicity. Control group participants will be able to receive the supplement after three months.

To refer a patient to this clinical trial call, 626-218-1133, or visit

Prostate Cancer Survival Rates at City of Hope Exceed National Averages

Ranked by U.S. News & World Report as one of the top 10 “Best Hospitals” for cancer in the U.S., City of Hope brings together the best and brightest clinicians and medical researchers to provide evidence-based treatment for patients nationwide.

Our Prostate Cancer Program is one of the largest programs of its kind in the western United States, and our experts are committed to providing optimal outcomes for patients to help transform the future of health by eliminating cancer.

Data collected between 2007 and 2016 shows that City of Hope consistently surpassed SEER national survival rates. Patients had a higher survival probability with City of Hope, as well as a higher percent difference over the SEER National survival estimates throughout all stages of prostate cancer, even 10 years postdiagnosis.

City of Hope is incredibly proud of the work our physicians and staff are doing within our Prostate Cancer Program, and we are excited to continue our commitment to excellence.

City of Hope’s adjusted* survival rate exceeds SEER National at all stages.

Prostate cancer survival graph City of Hope vs Seer 2022 results
*Proportional hazards regression adjusting for age (75+, 65-74, 55-64, 45-54 vs 15-44), race (Black, other vs white) and Stage (II, III, IV vs I).

 Percent Difference Between Age and Race Adjusted* Overall Survival Estimates by Stage

Prostate cancer survival rates by stage graph
*Proportional hazards regression survival estimates adjusting for age category (15-44, 45-54, 55-64, 65-74, 75+) and race (white, Black, other)

† Data were derived from City of Hope cancer registry (CNeXT) and SEER November 2019 Research Data Files as the comparator. All City of Hope patients in Duarte were diagnosed from 2007 through 2016, and City of Hope's follow-up cutoff date was 12/31/2017, to align with SEER data. Survival time was based on first occurring breast cancer diagnosis during the time period of interest.

These results illustrate the difference in the level of care City of Hope is providing to its prostate cancer patients in comparison to the average national outcomes.

The National Cancer Institute’s Surveillance, Epidemiology and End Results (SEER) Program is an authoritative source on cancer incidence and survival and provides cancer statistics to reduce the cancer burden among the U.S. population. It is supported by the Surveillance Research Program, which provides national leadership in cancer surveillance using analytical tools and methodological expertise in collecting, analyzing, interpreting and disseminating reliable population-based statistics.

To learn more about our outcomes for cancer treatment, visit us at

To begin the referral process for a patient with prostate cancer, call us at 800-826-HOPE, or visit